The treatment is a biosimilar that could compete with Regeneron Pharmaceuticals’ Eylea. Teva and Alvotech have been working together in a strategic partnership since 2020. Teva Pharmaceutical ...

A higher dose of Regeneron and Bayer's Eylea given every three or four months has shown efficacy in a pair of clinical trials, in a big boost for the multibillion-dollar product. The two studies ...

They all had severe disease and a high treatment burden with an average of 10 injections with Eylea (aflibercept), a widely-used VEGF inhibitor sold by Bayer and Regeneron, in the last 12 months.

boosted by strong demand for a new formulation of its blockbuster eye drug Eylea. The company also announced a new quarterly cash dividend and boosted its share-buyback program by $3 billion ...

The brokerage highlighted limited adoption of high-dose Eylea amid rising branded and biosimilar competition. UBS projects a 14% drop in Eylea revenue for 2025, with further declines in 2026.

"We are extremely pleased with this new step in the development of our biosimilar candidate to Eylea ®, as better access will benefit patients and their caregivers," said Joseph McClellan ...

This arrangement, the lawsuit claims, effectively lowered Eylea's selling price and provided Regeneron with a competitive advantage in the anti-VEGF medication market. The Department of Justice ...

Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD).

Flattening sales in the Eylea ophthalmology franchise were more than offset by strong sales from immunology drug Dupixent and oncology drug Libtayo. Despite strong competitive pressures facing the ...